Prof. Paul Gugliuzza shares his take on the legal dispute over Moderna’s patent for an mRNA molecule and what it illustrates about the nature of innovation today.
Published on September 7, 2022
Moderna’s vaccine lawsuit has a Philadelphia backstory
